Menu Search
Equities

scPharmaceuticals Inc

2SX:DUS

scPharmaceuticals Inc

Actions
  • Price (EUR)3.28
  • Today's Change0.06 / 1.86%
  • Shares traded--
  • 1 Year change-33.87%
  • Beta--
Data delayed at least 15 minutes, as of Nov 22 2024 15:30 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

scPharmaceuticals Inc. is a pharmaceutical company. The Company is focused on developing and commercializing products to optimize the delivery of infused therapies, advance patient care and reduce healthcare costs. The Company develops, internally and through strategic partnerships, products and solutions that aim to expand and advance the outpatient care of select acute conditions. Its lead product candidate, FUROSCIX, consists of its formulation of furosemide delivered via an on-body infuser. FUROSCIX is a formulation of furosemide contained in a pre-filled, Crystal Zenith cartridge and self- administered subcutaneously via a single-use, disposable and wearable on-body delivery system. The Companay’s pipeline programs include SCP-111 (furosemide injection) 80mg/mL is an investigational pH neutral aqueous furosemide formulation that is being developed for subcutaneous administration outside of the hospital setting, including patient self-administration in the home.

  • Revenue in USD (TTM)30.28m
  • Net income in USD-80.12m
  • Incorporated2013
  • Employees135.00
  • Location
    scPharmaceuticals Inc25 Burlington Mall Road, Suite 203BURLINGTON 01803United StatesUSA
  • Phone+1 (617) 517-0730
  • Fax+1 (302) 655-5049
  • Websitehttps://www.scpharmaceuticals.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.